BLOODPAC Quarterly Newsletter: Q3 2023
Summer 2023 News
Our invite-only Q3 meeting was generously hosted by Streck in Omaha, Nebraska. Our members spent the first day in working group sessions, followed by a day of day of updates, discussions and anticipated paths forward from each group.
BLOODPAC is thrilled to welcome Elizabeth Mansfield (VP, Regulatory Policy, Foundation Medicine) to our Scientific Co-Chair Committee! Liz has over 20 years of experience in regulatory affairs, including a decade of service at the FDA. Liz is a longtime member of our Analytical Validation working groups, and we are so excited she is joining BLOODPAC's leadership!
BLOODPAC welcomes Genece, our newest member! Genece Health is committed to advancing the field of oncology with the goal of providing an accessible tool to identify cancer earlier in its progression.
Last month, BLOODPAC hosted a panel discussion at the Next Generation Dx 2023 Summit on our work in developing and executing a strategic plan for MRD implementation. Thank you panelists Gregory Jones (Head of Precision Diagnostics, NeoGenomics) and Christina Lockwood (Associate Professor, University of Washington)!
This past spring, we initiated a call for feedback on our published AV protocols for ctDNA assays in order to ensure these documents continue to be up-to-date and useful. We were thrilled to receive insightful responses from a broad range of protocol users, and are working on incorporating this feedback into a revised version for publication in the new year.
Upcoming Events
October 4th, 2023 at 12:40pm ET: In this event at the Festival of Genomics and Biodata, BLOODPAC members will discuss current progress and clinical advances in liquid biopsy for early cancer detection. Panelists include Jonathan Beer (Senior Director of Diagnostic Sciences, Bristol Meyers Squibb), Lauren Leiman (Executive Director, BLOODPAC), and Carl Barrett (VP Translational Sciences, Oncology, AztraZeneca).
October 24th, 2023 at 10:45am CET: Adam Corner (Market Development Manager, Bio-Rad) will be representing BLOODPAC in a talk at the ISBER Regional Symposium 2023 in Granada, Spain. Adam will speak about our work in the use of contrived materials and developing protocols for analytical validation for liquid biopsy.
November 8th, 2023 at 3pm ET: In this session at the Liquid Biopsy Surveillance and Early Detection Summit in Boston, Lauren Leiman (Executive Director, BLOODPAC), Angela Silvestro (Director, Companion Diagnostics, GSK), and Dan Stetson (Principal Scientist, AstraZeneca) will discuss BLOODPAC's work in creating lexicons and frameworks for MCED and MRD liquid biopsy assays.
November 20th, 2023 at 6pm CET: BLOODPAC's Executive Director, Lauren C. Leiman, will give a talk at the 2023 International Society of Liquid Biopsy (ISLB) Meeting on our work in developing harmonized global regulatory standards for liquid biopsy assays.
